Use of photodynamic therapy to enhance treatment with immuno-modulating agents

• US 20050267213A1
• Filed: 01/07/2005
• Published: 12/01/2005
• Est. Priority Date: 01/08/2004
• Status: Abandoned Application

• Current Assignee: DUSA Pharmaceuticals Incorporated (Sun Pharmaceutical Industries Limited)
• Original Assignee: DUSA Pharmaceuticals Incorporated (Sun Pharmaceutical Industries Limited)
• Inventors: Gold, Michael, Lundahl, Scott, Goldman, Mitchel, Sowyrda, Paul
• Application Number:
  US11/030,311
• Publication Number:
  US 20050267213A1
• Time in Patent Office: Days
• US Class Current: 514/561
• CPC Class Codes: A61N 5/062 Photodynamic therapy, i.e. excitation of an agent
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders

Abstract

Methods of enhancing the efficacy and safety of treatment with immuno-modulating agents are provided. The inventive methods combine treatment with immuno-modulating agents with photodynamic therapy (PDT). PDT can be administered before, during or after administration of the immuno-modulating agent. Combination therapy achieves at least the same efficacy as immuno-modulatory therapy in less time, with less immuno-modulating agent and fewer side-effects.

Claims

1. A method of treating autoimmune disease in a patient comprising administering to said patient an immuno-modulating agent and a photosensitizer and

exposing said patient to light.

2. The method of claim 1, wherein said disease is psoriasis.

3. The method of claim 1, wherein said immuno-modulating agent is an immuno-suppressive agent.

4. The method of claim 1, wherein said immuno-modulating agent is a protein based immuno-suppressive agent.

5. The method of claim 1, wherein said immuno-modulating agent is an immuno-enhancing agent.

6. The method of claim 1, wherein said immuno-modulating agent is a protein based immuno-enhancing agent.

7. The method of claim 1, wherein said photosensitizer is aminolevulinic acid (ALA).

8. The method of claim 1, wherein said photosensitizer is a chemical salt or other chemical derivative of aminolevulinic acid.

9. The method of claim 1, wherein said photosensitizer is applied topically.

10. The method of claim 1, wherein administration of said photosensitizer and exposure of said patient to light occurs prior to administration of said immuno-modulating agent.

11. The method of claim 1, wherein administration of said photosensitizer and exposure of patient to light occurs after administration of said immuno-modulating agent.

12. The method of claim 1, wherein administration of said photosensitizer and exposure of said patient to light is concurrent with administration of said immuno-modulating agent.

13. The method of claim 1 wherein the light is blue light.

14. The method of claim 1 wherein the light is red light.

15. The method of claim 1 wherein the light is pulsed light.

16. The method of claim 1 wherein the light is laser light.

17. A method of treating a malignant lesion in a patient comprising administering to said patient an immuno-modulating agent and a photosensitizer and

exposing said patient to light.

18. A method of treating a disease in a patient comprising administering to said patient an immuno-modulating agent and a photosensitizer and

exposing said patient to light,

wherein said disease is a condition related to hyper-proliferative cells.

19. A method of enhancing the efficacy of an immuno-modulating agent comprising administering to a patient undergoing therapy with an immuno-modulating agent a photosensitizer and

exposing said patient to light.

20. The method of claim 19, wherein said therapy is directed at treating psoriasis.

21. The method of claim 19, wherein said therapy is directed at treating a malignant lesion.

22. The method of claim 19, wherein said therapy is directed at treating a condition related to hyper-proliferative cells.

23. The method of claim 19, wherein said immuno-modulating agent is an immuno-suppressive agent.

24. The method of claim 19, wherein said immuno-modulating agent is a protein based immuno-suppressive agent.

25. The method of claim 19, wherein said immuno-modulating agent is an immuno-enhancing agent.

26. The method of claim 19, wherein said immuno-modulating agent is a protein based immuno-enhancing agent.

27. The method of claim 19, wherein said photosensitizer is aminolevulinic acid (ALA).

28. The method of claim 19, wherein said photosensitizer is a chemical salt or other chemical derivative of aminolevulinic acid.

29. The method of claim 19, wherein said photosensitizer is applied topically.

30. The method of claim 19, wherein administration of said photosensitizer and exposure of said patient to light occurs prior to administration of said immuno-modulating agent.

31. The method of claim 19, wherein administration of said photosensitizer and exposure of patient to light occurs after administration of said immuno-modulating agent.

32. The method of claim 19, wherein administration of said photosensitizer and exposure of said patient to light is concurrent with administration of said immuno-modulating agent.

33. The method of claim 19, wherein the light is blue light.

34. The method of claim 19, wherein the light is red light.

35. The method of claim 19, wherein the light is pulsed light.

36. The method of claim 19, wherein the light is laser light.